Cardiovascular Outcome of the SGLT2 Inhibitor in Acute Myocardial Infarction: A Meta-Analysis

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Acute myocardial infarction (AMI) poses a risk for subsequent cardiovascular events.
• Sodium-glucose co-transporter 2 inhibitors (SGLT2-Is) are recommended for AMI treatment, but their impact on post-AMI outcomes is debated.
• This study investigates the effect of SGLT2-Is on cardiovascular outcomes following AMI.

Purpose of the Study:

• To evaluate the efficacy of SGLT2 inhibitors in reducing cardiovascular events post-AMI.
• To assess the impact of SGLT2 inhibitors on all-cause mortality and heart failure readmission after AMI.

Main Methods:

• A systematic review and meta-analysis of case-control studies.
• Searched PubMed, Web of Science, and Embase databases up to April 2024.
• Extracted data on study characteristics, participant demographics, and cardiovascular outcomes, including adjusted odds ratios and confidence intervals.

Main Results:

• Eight studies were included in the analysis.
• SGLT2-I use was associated with a significant reduction in heart failure hospitalization (OR: 0.66, 95% CI 0.57-0.76).
• SGLT2-I use also significantly lowered the incidence of major cardiovascular adverse events (OR: 0.79, 95% CI 0.70-0.89) but did not affect all-cause mortality (OR: 0.84, 95% CI 0.69-1.02).

Conclusions:

• SGLT2 inhibitor therapy post-AMI effectively reduces the risk of heart failure hospitalization.
• SGLT2 inhibitors are associated with a lower incidence of major adverse cardiovascular events following AMI.
• SGLT2 inhibitors do not demonstrate a significant effect on all-cause mortality in patients after AMI.